

Omgo E Nieweg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8616173/publications.pdf>

Version: 2024-02-01

58
papers

7,163
citations

201674
27
h-index

168389
53
g-index

60
all docs

60
docs citations

60
times ranked

4209
citing authors

#	ARTICLE	IF	CITATIONS
1	BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting. <i>Pathology</i> , 2022, 54, 6-19.	0.6	3
2	Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma. <i>JAMA Surgery</i> , 2022, 157, 335.	4.3	20
3	Effect of the time interval between melanoma diagnosis and sentinel node biopsy on the size of metastatic tumour deposits in node-positive patients. <i>European Journal of Cancer</i> , 2022, 167, 133-141.	2.8	3
4	Time interval between diagnostic excision-biopsy of a primary melanoma and sentinel node biopsy: effects on the sentinel node positivity rate and survival outcomes. <i>European Journal of Cancer</i> , 2022, 167, 123-132.	2.8	4
5	Neoadjuvant dabrafenib and trametinib (D+T) for stage III melanoma: Long-term results from the NeoCombi trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9580-9580.	1.6	1
6	Cost-effectiveness of targeted genomic risk provision to prevent skin cancer: Results of a randomized trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10536-10536.	1.6	0
7	Technologic (R)Evolution Leads to Detection of More Sentinel Nodes in Patients with Melanoma in the Head and Neck Region. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1357-1362.	5.0	6
8	Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. <i>Nature Medicine</i> , 2021, 27, 256-263.	30.7	190
9	Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma. <i>Annals of Oncology</i> , 2021, 32, 766-777.	1.2	22
10	Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies. <i>European Journal of Cancer</i> , 2021, 153, 8-15.	2.8	1
11	The prognostic value of tumor mitotic rate in children and adolescents with cutaneous melanoma: A retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 910-919.	1.2	10
12	Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2019, 20, 948-960.	10.7	346
13	Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIBâ€C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 961-971.	10.7	126
14	Clinical importance and surgical management of sentinel lymph nodes in the popliteal fossa of melanoma patients. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1706-1711.	1.0	5
15	De la imagen intervencionista a la guÃa intraoperatoria: nuevas perspectivas combinando herramientas avanzadas y navegaciÃ³n con la cirugÃa radioguiada. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2018, 37, 28-40.	0.0	7
16	Determining optimal sequencing of anti-PD-1 and BRAF-targeted therapy: A phase II randomised study of neoadjuvant pembrolizumab with/without dabrafenib and trametinib (D+T) in BRAF V600 mutant resectable stage IIIB/c/d melanoma (NeoTrio trial).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS9604-TPS9604.	1.6	8
17	Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. <i>New England Journal of Medicine</i> , 2017, 376, 2211-2222.	27.0	1,087
18	Role of sentinel lymph node biopsy as a staging procedure in patients with melanoma: A critical appraisal. <i>Australasian Journal of Dermatology</i> , 2017, 58, 268-273.	0.7	2

#	ARTICLE	IF	CITATIONS
19	Reply to comment on: Detailed Pathological Examination of Completion Node Dissection Specimens and Outcome in Melanoma Patients with Minimal (<0.1Åmm) Sentinel Lymph Node Metastases. Annals of Surgical Oncology, 2017, 24, 660-660.	1.5	1
20	Outcome of Melanoma Patients Who Did Not Proceed to Sentinel Node Biopsy After Preoperative Lymphoscintigraphy. Annals of Surgical Oncology, 2017, 24, 117-126.	1.5	11
21	Sentinel Lymph Node Biopsy: Evolution of the Technique Since the Original Description by Morton et al. in 1992. Critical Reviews in Oncogenesis, 2016, 21, 7-17.	0.4	4
22	Radioguided Sentinel Lymph Node Mapping and Biopsy in Cutaneous Melanoma. , 2016, , 151-163.		1
23	Radioguided Monitoring of Systemic Leakage During Isolated Limb Perfusion for Melanoma. , 2016, , 359-369.		0
24	Isolated Limb Perfusion for Melanoma. , 2016, , 355-373.		0
25	Detailed Pathological Examination of Completion Node Dissection Specimens and Outcome in Melanoma Patients with Minimal (<0.1Åmm) Sentinel Lymph Node Metastases. Annals of Surgical Oncology, 2015, 22, 2972-2977.	1.5	13
26	The history of sentinel node biopsy in head and neck cancer: From visualization of lymphatic vessels to sentinel nodes. Oral Oncology, 2015, 51, 819-823.	1.5	41
27	The History of Sentinel Lymph Node Biopsy. Cancer Journal (Sudbury, Mass), 2015, 21, 3-6.	2.0	45
28	Treatment of Regional Metastatic Melanoma of Unknown Primary Origin. Cancers, 2015, 7, 1543-1553.	3.7	8
29	Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma. New England Journal of Medicine, 2014, 370, 599-609.	27.0	1,203
30	Isolated limb perfusion with melphalan for melanoma. Journal of Surgical Oncology, 2014, 109, 332-337.	1.7	36
31	Current status of sentinel lymph node biopsy in patients with melanoma. Rozhledy V Chirurgii, 2014, 93, 485-90.	0.2	2
32	Isolierte Extremitätenperfusion bei Melanomen. , 2013, , 299-311.		1
33	Five-year follow-up of 16 melanoma patients with a Starz I-involved sentinel node in whom completion lymph node dissection was omitted. Melanoma Research, 2012, 22, 436-439.	1.2	6
34	Less false-negative sentinel node procedures in melanoma patients with experience and proper collaboration. Journal of Surgical Oncology, 2011, 104, 454-457.	1.7	46
35	Prognosis in Patients With Sentinel Node-Positive Melanoma Is Accurately Defined by the Combined Rotterdam Tumor Load and Dewar Topography Criteria. Journal of Clinical Oncology, 2011, 29, 2206-2214.	1.6	195
36	The Impact on Morbidity and Length of Stay of Early Versus Delayed Complete Lymphadenectomy in Melanoma: Results of the Multicenter Selective Lymphadenectomy Trial (I). Annals of Surgical Oncology, 2010, 17, 3324-3329.	1.5	177

#	ARTICLE	IF	CITATIONS
37	The Additional Value of SPECT/CT in Lymphatic Mapping in Breast Cancer and Melanoma. Journal of Nuclear Medicine, 2007, 48, 1756-1760.	5.0	111
38	The health-related quality of life of long-term survivors of melanoma treated with isolated limb perfusion. European Journal of Surgical Oncology, 2007, 33, 776-782.	1.0	49
39	Sentinel-Node Biopsy or Nodal Observation in Melanoma. New England Journal of Medicine, 2006, 355, 1307-1317.	27.0	1,679
40	Sentinel Node Biopsy for Early-Stage Melanoma. Annals of Surgery, 2005, 242, 302-313.	4.2	632
41	Thirty-five years of isolated limb perfusion for melanoma: Indications and results. British Journal of Surgery, 2005, 83, 1319-1328.	0.3	107
42	Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients. Journal of Surgical Oncology, 2005, 91, 107-111.	1.7	27
43	Major amputation for intractable extremity melanoma after failure of isolated limb perfusion. European Journal of Surgical Oncology, 2005, 31, 95-99.	1.0	25
44	Isolated Limb Perfusion Prolongs the Limb Recurrence-Free Interval After Several Episodes of Excisional Surgery for Locoregional Recurrent Melanoma. Annals of Surgical Oncology, 2004, 11, 491-499.	1.5	34
45	Isolated Limb Perfusion for Unresectable Melanoma of the Extremities. Archives of Surgery, 2004, 139, 1237.	2.2	74
46	Long-term results of a double perfusion schedule using high dose hyperthermia and melphalan sequentially in extensive melanoma of the lower limb. Melanoma Research, 2003, 13, 395-399.	1.2	22
47	Safety and efficacy of isolated limb perfusion in elderly melanoma patients. Annals of Surgical Oncology, 2002, 9, 968-974.	1.5	60
48	Reliability of sentinel lymph node biopsy for staging melanoma. British Journal of Surgery, 2002, 87, 484-489.	0.3	160
49	The Definition of a Sentinel Node. Annals of Surgical Oncology, 2001, 8, 538-541.	1.5	215
50	Sensitivity of sentinel node biopsy in melanoma. Journal of Surgical Oncology, 2001, 78, 223-224.	1.7	14
51	Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma. Journal of the American College of Surgeons, 1999, 188, 522-530.	0.5	55
52	Toxicity and morbidity of isolated limb perfusion. , 1998, 14, 224-231.		65
53	Technique of lymphatic mapping and sentinel node biopsy for melanoma. European Journal of Surgical Oncology, 1998, 24, 520-524.	1.0	39
54	Rationale for different approaches to combined melphalan and hyperthermia in regional isolated perfusion. European Journal of Cancer, 1997, 33, 1546-1550.	2.8	22

#	ARTICLE	IF	CITATIONS
55	Carbon dioxide laser for cutaneous melanoma metastases: Indications and limitations. European Journal of Surgical Oncology, 1997, 23, 435-438.	1.0	39
56	Systemic toxicity after isolated limb perfusion with melphalan for melanoma. European Journal of Surgical Oncology, 1996, 22, 521-527.	1.0	41
57	Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs. Journal of the American College of Surgeons, 1996, 182, 467-72.	0.5	27
58	Severe acute regional toxicity after normothermic or ??mild?? hyperthermic isolated limb perfusion with melphalan for melanoma. Melanoma Research, 1995, 5, 425-432.	1.2	33